ACTIVITY AND SAFETY OF A COMBINATION OF EPIRUBICIN, DOCETAXEL AND CISPLATIN AS NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED BREAST CANCER (LABC): A PRELIMINARY REPORT

被引：0
|
作者：
Avci, N. [1 ]
Kanat, O. [1 ]
Gokgoz, S. [1 ]
Tolunay, S. [1 ]
Topal, U. [1 ]
Cubukcu, E. [1 ]
Olmez, F. [1 ]
机构：
[1] Uludag Univ, Fac Med, Bursa, Turkey
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [41] Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Neoadjuvant capecitabine (X) plus clocetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Christaens, M.-R.
    Weltens, C.
    Drijkonngen, R.
    Van Ongeval, C.
    Van Steen, A.
    Paridaens, R.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 105 - 106
  • [43] Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin
    D'Agostino, G
    Distefano, M
    Greggi, S
    Salerno, M
    Ferrandina, G
    Poerio, A
    Mancuso, S
    Scambia, G
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (03) : 256 - 260
  • [44] Efficacy of combination treatment with epirubicin (EPI) plus docetaxel (DOC) in advanced breast cancer
    Hata, Y.
    Takahashi, M.
    Takahashi, H.
    Hosoda, M.
    Taguchi, K.
    Tamura, M.
    Tomioka, N.
    Ohsawa, S.
    Nakagawa, T.
    Matsuoka, S.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 277
  • [45] Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin
    Giuseppe D'Agostino
    Mariagrazia Distefano
    Stefano Greggi
    Maria Salerno
    Gabriella Ferrandina
    Antonella Poerio
    Salvatore Mancuso
    Giovanni Scambia
    [J]. Cancer Chemotherapy and Pharmacology, 2002, 49 : 256 - 260
  • [46] Response rate with weekly epirubicin and docetaxel as neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer (BC).
    Chen, SC
    Chang, HK
    Lin, YC
    Leung, WM
    Chang, JT
    Cheung, YC
    Hsueh, S
    Lo, YF
    Tsai, HP
    Chen, MF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 99S - 99S
  • [47] COMBINED TREATMENT FOR LOCALLY ADVANCED BREAST-CANCER (LABC)
    COLOZZA, M
    GORI, S
    BELSANTI, V
    MOSCONI, A
    ROSSETTI, R
    BASURTO, C
    ANASTASI, P
    LATINI, P
    MARANZANO, E
    CHECCAGLINI, F
    MERCATI, U
    TONATO, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 125 - 125
  • [48] Neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC):: preliminary safety and efficacy data from a multicentre phase II study
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 157 - 158
  • [49] Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer.
    Yardley, DA
    Whitworth, P
    Greco, FA
    Burris, HA
    White, M
    Thomas, M
    Dunbar, L
    Yost, K
    Hainsworth, JD
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S54 - S54
  • [50] Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel
    Gu, Xi
    Jia, Shi
    Wei, Wei
    Zhang, Wen-Hai
    [J]. TUMOR BIOLOGY, 2015, 36 (07) : 5529 - 5535
12345